drugset / Trial / NCT05974085
XPO-1 in Combination With RCHOP for DH/TH Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of Selinexor in combination with RCHOP in first-line treatment of patients with DH or TH lymphoma.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2023-12-31
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 60 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Background | Epirubicin | Small molecule | 75 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vincristine | Small molecule | 4 mg | — |